HIV Prevention With PrEP Among People on Opioid Replacement Therapy

What this study is about

The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.

Who can join (things the study team will check)

✅ You may be able to join if…

• HIV negative
• Ongoing behaviors with potential HIV exposure as assessed by a clinician
• Regularly engaged with their respective OAT program at least 3 days a week for the past 2 weeks
• Report willingness to return for follow-up visits

🚫 You may not be able to join if…

• Creatine clearance <30 mL/min or any medical condition or medication known to be contraindicated with the use of Emtricitabine/Tenofovir Alafenamide (F/TAF) or Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
• Taken PrEP within the last 24 hours at the time of screening or enrollment
• Deemed appropriate by a clinician for HIV Post-Exposure Prophylaxis at the time of screening or enrollment

Where this trial is running

• Sheldon M Chumir Health Centre, Calgary, Alberta, Canada
• Queen City Wellness Pharmacy, Regina, Saskatchewan, Canada
• Mayfair Drugs Pharmacy, Saskatoon, Saskatchewan, Canada
• Pharmasave Riversdale Pharmacy, Saskatoon, Saskatchewan, Canada
• The Medicine Shoppe Pharmacy, Saskatoon, Saskatchewan, Canada
• Meadowgreen Pharmacy, Saskatoon, Saskatchewan, Canada